Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Sarcoma 1

Conditions

Melanoma 2Neoplasms 1Neoplasm Metastasis 1

Interventions

pembrolizumab 181Nivolumab 117Ipilimumab 97Dacarbazine 48trametinib 37dabrafenib 353-ingenyl angelate 35Vemurafenib 33cemiplimab 27atezolizumab 24Temozolomide 24binimetinib 23Paclitaxel 22Imiquimod 22encorafenib 17avelumab 17Carboplatin 17Aminolevulinic Acid 17spartalizumab 16cobimetinib 16Cyclophosphamide 15Cisplatin 15Fluorouracil 14talimogene laherparepvec 13HhAntag691 11Gels 11Drug Therapy 11Bevacizumab 11lenvatinib 10durvalumab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × elesclomol × Dermatologic × Clear all
NCT00084214 2014-03-06

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

Synta Pharmaceuticals Corp.

Phase 1/2 Completed
103 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

NCT00522834 2014-03-04

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

Synta Pharmaceuticals Corp.

Phase 3 Terminated
630 enrolled
Dermatologic

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡